Stephen E. Gould - 09 Feb 2023 Form 4 Insider Report for Atreca, Inc.

Role: Chief Scientific Officer
Signature: /s/ Courtney Phillips, Attorney-In-Fact
Issuer symbol: N/A
Transactions as of: 09 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 13 Feb 2023, 19:53:35 UTC
Previous filing: 17 Jun 2022
Next filing: 04 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BCEL	Class A Common Stock	Award	$0	+32,500		$0.000000	32,500	09 Feb 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BCEL	Employee stock option (right to buy)	Award	$0	+130,000		$0.000000	130,000	09 Feb 2023	Class A Common Stock	130,000	$1.49	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person received an award of 32,500 restricted stock units on February 9, 2023, vesting in three equal annual installments beginning on August 1, 2023. Each restricted stock unit represents a right to receive one share of Atreca Class A Common Stock upon vesting.
F2	1/48 of the Option vests in equal monthly installments as measured from January 1, 2023. If applicable, vesting accelerates as provided in, and subject to the terms and conditions of, that certain Executive Employment Agreement between the Issuer and the Reporting Person, as may be amended from time to time.